An interventional study of Animal-Based Oil Group and Plant-Based Oil Group in Sarcopenia and Sarcopenia in Elderly, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Sarcopenia by Chang Gung Memorial Hospital — 8 open to participants now, 8 under way, none of them phase 3. Sarcopenia · Chang Gung Memorial Hospital.
Among the 14 studies in Sarcopenia by Chang Gung Memorial Hospital, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 11th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →8 of the 14 studies in Sarcopenia by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–80
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 65+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 50+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 50+
By country, each count listing its studies:
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 50 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 90 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 90 across the 11 interventional studies, 150 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
3 of the studies in Sarcopenia by Chang Gung Memorial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896603Chang Gung Memorial HospitalPhysical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia | 2027-07 |
| NCT07180134Chang Gung Memorial HospitalHealth Informatics and Resistance Exercise for Symptom Management and Quality of Life in Post-Esophagectomy Patients | 2027-07-31 |
| NCT06666881Chang Gung Memorial HospitalSkeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Sarcopenia by Chang Gung Memorial Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Population aging has become a significant global concern, and Taiwan is set to officially enter the "super-aged society" in 2025. As individuals age, various physiological functions gradually decline, including a reduction in muscle mass, which is a key aspect of the aging process.
This interventional study aims to investigate the effects of leucine-rich protein combined with polyunsaturated fatty acid supplementation on middle-aged and elderly individuals (aged 50 and above) who are at high risk for sarcopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will supplement with animal-based poly-unsaturated oil. The supplementation will be maintained for 12 weeks.
Dietary Supplement: Animal-Based Oil Group
Participants in this group will supplement with plant-based poly-unsaturated oil. The supplementation will be maintained for 12 weeks.
Dietary Supplement: Plant-Based Oil Group
Participants in animal-based oil group will follow a diet in which the primary fat source is animal-based oil. The diet will supplement for 12 weeks.
Participants in plant-based oil group will follow a diet in which the primary fat source is plant-based oil. The diet will supplement for 12 weeks.
muscle mass
Utilize Bioelectrical Impedance Analysis (BIA) to measure the Appendicular Skeletal Muscle Mass Index Level (ASMI) (kg/m\^2)
Time frame: baseline, 12 weeks
muscle function
utilize handgrip dynamometer to measure the hand grip strength (kg).
Time frame: baseline, 12 weeks
physical function
To assess the participant's walking speed over a 4-meter distance.
Time frame: baseline, 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Apr 2026, 9 months later.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 9 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital →